European Heart Journal-Cardiovascular Pharmacotherapy

Papers
(The TQCC of European Heart Journal-Cardiovascular Pharmacotherapy is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
The search for the holy grail: the balance between the risk of thrombosis and bleeding in patients108
Early initiation of SGLT2 inhibitors after acute myocardial infarction86
Sex-related differences in cardiovascular pharmacotherapy: fiction or fact? Why can’t we see the evidence?76
Anticoagulation for the prevention of arterial thromboembolism in cancer patients by primary tumour site: a systematic review and meta-analysis of randomized trials61
Effects of renin–angiotensin system blockers on outcomes from COVID-19: a systematic review and meta-analysis of randomized controlled trials53
Finerenone for Diabetic Hearts: A Critical Appraisal of MACE Benefits and the Research Road Ahead51
The role of aetiology in determining anticoagulation effectiveness for the treatment of left ventricular thrombus48
Comparative cardiovascular and renal effectiveness of empagliflozin and dapagliflozin: Scandinavian cohort study47
Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee47
Associations of omega-3 fatty acids vs. fenofibrate with adverse cardiovascular outcomes in people with metabolic syndrome: propensity matched cohort study44
Implementation of novel antithrombotic treatment strategies and outcome improvements in patients with myocardial infarction and atrial fibrillation over 20 years: a nationwide cohort study40
Effectiveness and safety of sodium-glucose cotransporter-2 inhibitor initiation in sacubitril-valsartan users with heart failure: a population-based cohort study40
Prognostic benefit of glucagon-like peptide-1 receptor agonists addition to sodium-glucose cotransporter 2 inhibitors in patients with atherosclerotic cardiovascular disease and heart failure: a cohor37
Editorial on incidence and outcomes of transient new onset atrial fibrillation complicating acute coronary syndromes: results from a systematic review and meta-analysis36
Edoxaban for 12 vs. 3 months in cancer-associated isolated distal deep vein thrombosis according to different doses: insights from the ONCO DVT study34
Flecainide to prevent atrial arrhythmia after patent foramen ovale closure, Rationale and design of the randomized AFLOAT study31
Net clinical benefit of extended dual pathway inhibition according to baseline risk in patients with chronic coronary syndrome: a COMPASS substudy30
Impact of transfusion strategy on platelet aggregation and biomarkers in myocardial infarction patients with anemia29
Subcutaneous furosemide patch: heart failure decongestion ‘from the comfort of your home’28
SGLT2 inhibitors are associated with improved long-term survival in Takotsubo syndrome: insights from large-scale real-world data28
All about clinical trials28
Management of patients with congenital bleeding disorders and cardiac indications for antithrombotic therapy27
Cardiac adverse drug reactions to COVID-19 vaccines. A cross-sectional study based on the Europe-wide data26
Inhibition of interleukin-1 or -6 after myocardial infarction: pros, cons, and future perspectives26
Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis25
When randomization is not enough: divergent β-blocker trials and the illusion of universal causality25
New ways of mitigating aldosterone in cardiorenal disease25
Anti-inflammatory pharmacotherapy in patients with cardiovascular disease24
Aspirin may take a back row seat for non-ST-segment elevation acute coronary syndrome after percutaneous coronary intervention24
Safety and efficacy of early initiation of sodium-glucose cotransporter-2 inhibitors after an acute coronary syndrome event: a meta-analysis of randomized controlled trials24
Authors’ reply to: ‘preventing atrial fibrillation with SGLT2 inhibitors: time, sex, and substrate’ by Karakasis et al .24
Long-term antiplatelet monotherapy after PCI: searching for the smart choice23
OCEAN trial: rethinking long-term anticoagulation after atrial fibrillation ablation22
Impact of left ventricular ejection fraction on the effect of beta-blocker therapy on 1-year mortality in acute coronary syndrome patients22
SGLT2 inhibitors in heart failure with tricuspid regurgitation: clinical interpretation and future directions21
Cardiovascular prevention and risk factors21
Net clinical benefit of extended dual pathway inhibition in chronic coronary syndrome as classified by the 2024 ESC criteria: a COMPASS substudy21
Antithrombotic therapy and cardiovascular outcomes after transcatheter aortic valve implantation in patients without indications for chronic oral anticoagulation: a systematic review and network meta-20
Longitudinal loop diuretic use in patients with HFrEF initiated with sodium–glucose cotransporter 2 inhibitors20
Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease19
Long-term effects of phosphodiesterase-5 inhibitors on cardiovascular outcomes and death: a systematic review and meta-analysis19
De-escalation versus shortening of dual antiplatelet therapy19
News in cardiovascular pharmacotherapy from the ACC.24 Meeting18
Correction to: Aspirin-free strategy for percutaneous coronary intervention in acute coronary syndrome based on the subtypes of acute coronary syndrome and high bleeding risk: the STOPDAPT-3 trial18
Focus on different lipid-lowering treatment and genetic testing for optimal pharmacotherapy use in the clinic18
From “bridging specialties” to “owning the patient”: rethinking accountability in Cardiovascular-Kidney-Metabolic syndrome care18
Apixaban outcomes in atrial fibrillation patients with a single-dose reduction criterion: ASPIRE 1-year results18
The dual endothelin-1 antagonist aprocitentan alleviates mitochondrial oxidative stress in human cardiac fibroblasts17
Adenosine as adjunctive therapy in acute coronary syndrome: a meta-analysis of randomized controlled trials17
Pharmacotherapy of patients with heart failure and atrial fibrillation: let's get the evidence!17
Chronic coronary syndrome and new-onset atrial fibrillation or venous thromboembolism: how best to manage antithrombotic therapy strategies17
Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis16
Entering a new era of antiplatelet therapy: the 4D-ACS trial16
Stroke risk stratifications according to CHA2DS2-VASc vs. CHA2DS2-VA in patients with atrial fibrillation: insights from the GLORIA-AF registry16
Reply to ‘Sacubitril/valsartan in heart failure: a critical look at dementia risk and future study pathways’16
Are NOACs always the best strategy in elderly AF patients?16
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202316
Correction to: Interdisciplinary recommendations for recurrent hyperkalaemia: insights from the GUARDIAN-HK European Steering Committee16
A farewell to professor Stefan Agewall from the ESC Working Group on Cardiovascular Pharmacotherapy15
What's new in pharmacotherapy at ESC Congress 2023?15
Initial statin dose after myocardial infarction and long-term cardiovascular outcomes15
Initiation of eplerenone vs. spironolactone and all-cause mortality in HFrEF: linked database study15
Predicting performance of the HAS-BLED and ORBIT bleeding risk scores in patients with atrial fibrillation treated with Rivaroxaban: Observations from the prospective EMIR Registry15
Seeking for the boundaries of de-escalation in antiplatelet therapy for acute coronary syndrome14
Impact of single vs. dual local anaesthetic regimen on the efficacy and safety of percutaneous stellate ganglion block for electrical storm: new insights from the STAR study14
Effectiveness and safety of direct oral anticoagulation vs. warfarin in frail patients with atrial fibrillation14
Different aspects of pharmacological heart failure treatment14
Association of PCSK9 inhibitors with mortality: insights from a retrospective cohort analysis14
Cardiovascular outcomes in hepatitis C virus infected patients treated with direct acting antiviral therapy: a retrospective multi-institutional study14
New pharmacological agents and novel cardiovascular pharmacotherapy strategies in 202214
Is the TIME study on antihypertensive therapy and chronotropic effects on cardiovascular outcomes a pragmatic trial?14
New-onset syncope in diabetic patients treated with sodium-glucose cotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors: a Chinese population-based cohort study13
An old drug in a new era: digitoxin in the spotlight after DIGIT-HF13
Cardiovascular disease and cardiovascular pharmacotherapy: the challenges and the research continue13
Dual antiplatelet therapy duration after percutaneous coronary intervention in patients with indication to oral anticoagulant therapy. A systematic review and meta-analysis of randomized controlled tr13
Diuretic strategies in acute heart failure: a systematic review and network meta-analysis of randomized clinical trials13
Who requires longer-term anticoagulation therapy for venous thromboembolism from the perspective of precision medicine?13
Inotropes and mortality in patients with cardiogenic shock: an instrumental variable analysis from the SWEDEHEART registry13
Cardiotoxicity in dual immune checkpoint inhibitors: a critical appraisal of signal interpretation and future directions13
Extensive LDL-cholesterol lowering by PCSK9 inhibitor on the risk of venous thrombosis13
Immunomodulatory effect of different statin regimens on regulatory T-cells in patients with acute coronary syndrome: a systematic review and network meta-analysis of randomized clinical trials13
Corrigendum to: Facing the challenge of polypharmacy when prescribing for older people with cardiovascular disease. A review by the European Society of Cardiology Working Group on Cardiovascular Pharm12
Does LDL-C determination method affect statin prescribing for primary prevention? A register-based study in Southern Denmark12
Correction to: Urate-lowering therapy in cardiovascular pharmacotherapy: from Mendelian randomization data to cardio–renal–metabolic risk modulation12
Intracoronary adjunctive therapies for ST-elevation myocardial infarction: a network meta-analysis of trials11
An aspirin-free strategy for percutaneous coronary intervention in patients with diabetes: a pre-specified subgroup analysis of the STOPDAPT-3 trial11
Sodium–glucose cotransporter 2 inhibitor use in early-phase acute coronary syndrome with severe heart failure11
Kidney function and acid–base status as gatekeepers of natriuretic and diuretic responsiveness in chronic HF: insights from the DEA-HF clinical trial11
RNA-targeted therapeutics in cardiovascular disease: the time is now11
We have much more to learn about sodium-glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists11
Effect of SGLT2i on kidney outcomes of individuals with type 2 diabetes according to body mass index: nationwide cohort study11
Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study10
Finerenone efficacy in patients with chronic kidney disease, type 2 diabetes and atherosclerotic cardiovascular disease10
Use of methylphenidate is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nationwide nested case-control study10
Reply to Zhang and Lou: beta-blockers after myocardial infarction should be guided by indication, ejection fraction, and contemporary evidence10
FLOW trial stopped early due to evidence of renal protection with semaglutide10
Impact of body mass on P2Y12-inhibitor de-escalation in acute coronary syndromes—a substudy of the TROPICAL-ACS trial10
0.084304809570312